High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

BACKGROUND: Eribulin, a nontaxane synthetic inhibitor of microtubule dynamics, is widely used to manage locally advanced or metastatic breast cancer (MBC). Eribulin has demonstrated immunomodulatory activity on the tumour microenvironment. Baseline neutrophil-to-lymphocyte ratio (NLR), a marker of i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer
Main Authors: Miyoshi, Yasuo, Yoshimura, Yuta, Saito, Kenichi, Muramoto, Kenzo, Sugawara, Michiko, Alexis, Karenza, Nomoto, Kenichi, Nakamura, Seigo, Saeki, Toshiaki, Watanabe, Junichiro, Perez-Garcia, Jose Manuel, Cortes, Javier
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7297864/
https://ncbi.nlm.nih.gov/pubmed/32133606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01067-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados